Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 7/20 | 0.49 |
| ▸ | MAP2K7 | O14733 | 5/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2778534 | 0.97 | KDR (0.48) | KDRTNNI3KMAP2K7HSD17B10FGFR4 | |
| SCHEMBL2778276 | 0.94 | KDR (0.51) | KDRTNNI3KMAP2K7RAF1MAPK14 | |
| SCHEMBL2778309 | 0.84 | KDR (0.44) | KDRTNNI3KMAP2K7HSD17B10FGFR4 | |
| SCHEMBL2777187 | 0.84 | HSD17B10 (0.48) | KDRTNNI3KHSD17B10FGFR4KDM4E | |
| SCHEMBL12972241 | 0.83 | KDR (0.54) | KDRTNNI3KMAP2K7FGFR4RAF1 | |
| SCHEMBL2779000 | 0.82 | HSD17B10 (0.43) | HSD17B10KDM4E | |
| SCHEMBL2777261 | 0.81 | HSD17B10 (0.45) | KDRTNNI3KHSD17B10FGFR4KDM4E | |
| SCHEMBL2708240 | 0.80 | KDR (0.48) | KDRTNNI3KMAP2K7RAF1 | |
| SCHEMBL2796677 | 0.79 | KDR (0.45) | KDR | |
| SCHEMBL12972259 | 0.78 | KDR (0.62) | KDRTNNI3KRAF1MAPK14BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | KDR 479/4885TNNI3K 270/4885MAP2K7 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.